Tralokinumab is in development for the treatment of moderate to severe atopic dermatitis (AD) uncontrolled with currently available therapies in adult patients who are candidates for systematic therapy. AD is a chronic inflammatory skin disease that affects both children and adults and is characterised by redness, itchiness, and scaling of the skin. Some people only have small patches of dry skin, but others may experience widespread red, inflamed skin all over the body. Patients with moderate to severe AD could come across with sleep disturbances, anxiety, depression, and poor quality of life. Currently, the management of AD involves the removal or treatment of trigger factors that contribute to the development of the disease.
Tralokinumab is a human monoclonal antibody that binds and neutralises the effect of the protein interleukin 13 (IL-13), which plays a key role in triggering immune system responses in patients leading to AD. Tralokinumab is taken subcutaneously (SC), and trial evidence suggests it has been associated with improvements in disease symptoms. If licensed, tralokinumab will offer an additional treatment option for adults with moderate to severe AD who are candidates for systematic therapy, who may or may not use steroid cream previously.
BMS-986165 is in clinical development for moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Psoriasis is an inflammatory disease whereby the body’s immune system becomes over-active resulting in the life cycle of skin cells to drastically speed up. This causes a build-up of red, scaly, flaky and itchy patches of skin to appear that often involve the knees, elbows, scalp and lower back. Plaque psoriasis is thought to be caused by a combination of genetic susceptibility and triggers such as stress, smoking and hormonal changes. Treatment is determined by the area of skin affected and the severity of the plaque psoriasis and may include a combination of topical, phototherapy and systemic (oral or injected) therapies.